Development of Potent and Selective Tissue Transglutaminase Inhibitors: Their Effect on TG2 Function and Application in Pathological Conditions  by Badarau, Eduard et al.
Article
Development of Potent and Selective Tissue
Transglutaminase Inhibitors: Their Effect on TG2
Function and Application in Pathological ConditionsGraphical AbstractHighlightsd Irreversible tissue transglutaminase (TG2) inhibitors of high
selectivity and potency
d Target the Ca2+ activated form of TG2 in the intra- and/or
extracellular space
d Reactive with intracellular TG2 and block its translocation
into the matrix
d Effective in blocking hypertensive nephrosclerosis in animal
modelsBadarau et al., 2015, Chemistry & Biology 22, 1347–1361
October 22, 2015 ª2015 Elsevier Ltd All rights reserved
http://dx.doi.org/10.1016/j.chembiol.2015.08.013Authors
Eduard Badarau, Zhuo Wang,
Dan L. Rathbone, ..., Said El Alaoui,
Milda Bartkeviciute, Martin Griffin
Correspondence
m.griffin@aston.ac.uk
In Brief
Badarau et al. design and develop high-
potency TG2-specific irreversible
inhibitors that show reactivity with the
intracellular active form of TG2, leading to
inhibition of its translocation into the
extracellular matrix. The compounds are
effective in inhibiting in vitro angiogenesis
and hypertensive nephrosclerosis in
animal models.
Chemistry & Biology
ArticleDevelopment of Potent and Selective Tissue
Transglutaminase Inhibitors: Their Effect on TG2
Function and Application in Pathological Conditions
Eduard Badarau,1,4,5 Zhuo Wang,1,4 Dan L. Rathbone,1 Andrea Costanzi,1 Thomas Thibault,1 Colin E. Murdoch,2
Said El Alaoui,3 Milda Bartkeviciute,2 and Martin Griffin1,*
1School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK
2Aston Medical Research Institute, Aston Medical School, Aston University, Aston Triangle, Birmingham B4 7ET, UK
3Covalab France, 11 avenue Albert Einstein, 69100 Villeurbanne, France
4Co-first author
5Present address: European Institute of Chemistry and Biology, 2 Rue Robert Escarpit, 33607 Pessac, France
*Correspondence: m.griffin@aston.ac.uk
http://dx.doi.org/10.1016/j.chembiol.2015.08.013SUMMARY
Potent-selective peptidomimetic inhibitors of tissue
transglutaminase (TG2) were developed through a
combination of protein-ligand docking and molecu-
lar dynamic techniques. Derivatives of these inhibi-
tors weremadewith the aim of specific TG2 targeting
to the intra- and extracellular space. A cell-perme-
able fluorescently labeled derivative enabled detec-
tion of in situ cellular TG2 activity in human umbilical
cord endothelial cells and TG2-transduced NIH3T3
cells, which could be enhanced by treatment of cells
with ionomycin. Reaction of TG2with this fluorescent
inhibitor in NIH3T3 cells resulted in loss of binding
of TG2 to cell surface syndecan-4 and inhibition of
translocation of the enzyme into the extracellular
matrix, with a parallel reduction in fibronectin depo-
sition. In human umbilical cord endothelial cells,
this same fluorescent inhibitor also demonstrated a
reduction in fibronectin deposition, cell motility, and
cord formation in Matrigel. Use of the same inhibitor
in a mouse model of hypertensive nephrosclerosis
showed over a 40% reduction in collagen deposition.
INTRODUCTION
Transglutaminases (TGs) belong to a family of protein crosslink-
ing enzymes that catalyze an acyl transfer reaction between
the g-carboxamide group of peptide-bound glutamine and the
ε-amino group of peptide-bound lysine (or a suitable primary
amine) resulting in formation of a ε(g-glutamyl)lysine isopeptide
bond (Griffin et al., 2002). In mammals, eight catalytically
active TGs, each Ca2+-dependent, are found in this family, of
which tissue transglutaminase (TG2) is probably the most ubiq-
uitous in human tissues. The current challenges in studying
the role of TG2 are to (1) develop inhibitors that target TG2
and not other members of the TG family (specificity); (2) investi-
gate independently the intracellular and extracellular roles of
the enzyme (cell permeability); (3) characterize the effect ofChemistry & Biology 22, 1347–1specifically inhibiting TG2 crosslinking activity in physiological/
pathological conditions. TG2 is involved in a host of human dis-
eases such as celiac disease, cancer, fibrosis, multiple sclerosis,
and neurodegeneration (Wang and Griffin, 2012). As a conse-
quence, TG2 has become a potential therapeutic target for
the treatment of these pathological conditions (Badarau et al.,
2013a).Moreover, since TG2 is found both in the intra- and extra-
cellular space, both targeted specificity for TG2 itself and spe-
cific targeting to a particular subcellular space are needed.
We recently described inhibitors aimed at targeting only the
extracellular space (Badarau et al., 2013b; Griffin et al., 2008).
These molecules incorporate two key polar groups in their
structure in order to assure their high hydrophilic character: a
carboxylate moiety and a charged warhead represented either
by a dimethylsulfonium (Griffin et al., 2008) or by an imidazolium
function (Badarau et al., 2013b). Despite their activities in the
low micromolar range, these derivatives have great potential
because of their high aqueous solubility and their excellent
cellular toxicity profile. In fact, since their intracellular access is
restrained, these inhibitors show very little toxicity in cells up to
750 mM over 72 hr (Wang and Griffin, 2013). They have also
shown considerable success in proof-of-concept studies in
animal models of kidney fibrosis over 120 days without any signs
of toxicity but with significant improvements in kidney function
(Huang et al., 2009; Johnson et al., 2007). However, the major
drawback with these extracellular acting TG inhibitors is potency
and specificity. Therefore, the first objective of our work was to
design potent, highly specific TG2 inhibitors that could be used
for targeting the intra- and/or extracellular space, were not toxic
in cellular systems, and had the potential to be used in preclinical
studies.
In the design of this new family of inhibitors, we were also very
much aware that, once deposited into the extracellular matrix
(ECM), TG2 is tightly associated with its potential substrates
and is not easily accessible; and that the secretion and translo-
cation of TG2 onto the cell surface and into the extracellular
matrix ECM, which is independent of the conventional ER/Golgi
pathway, requires the binding of TG2 to the cell surface heparan
sulfate proteoglycan syndecan-4. Importantly, the binding of
TG2 to this proteoglycan is highly favored by its compact closed
conformation (Wang et al., 2012; Lortat-Jacob et al., 2012).
Hence, a further objective in this work was to assess whether361, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1347
suitably labeled irreversible TG2 specific inhibitors that can
permeate the cell can also bind TG2 inside the cell thus both
inhibiting enzyme activity and locking it into its open confir-
mation. This is particularly important when considering TG2 as
a therapeutic target since TG2 in its open confirmation is likely
to be blocked in its translocation to the cell surface and into
the ECM because it is unable to bind effectively to cell surface
heparan sulfates (Wang et al., 2012). Moreover, if it doesmanage
to reach the ECM, e.g. from cell lysis, it reaches it in an inactive
form. Such inhibitors are likely to have a broad spectrum of appli-
cation in TG2-mediated human pathologic conditions in which
TG2 is acting either inside or outside the cell.
RESULTS
In developing the TG2 inhibitors, the work was divided into two
interlinked processes: in silico molecular modeling to first design
and then synthesize the inhibitors and then a series of studies
on their characterization. The latter included enzyme potency,
specificity, cell permeability, solubility, and in vitro ADME (ab-
sorption, distribution, metabolism, excretion) characterization
followed by an assessment of their potential application in bio-
logical systems using cell-based and in vivo preclinical models.
Generation of New Peptidomimetic TG2 Inhibitors
Molecular modeling was used to yield insights into the probable
binding pattern of our previous peptidic water-soluble deriva-
tives. The modeling approach was based on the Michaelis-
Menten complexes generated by docking of these compounds
with the open conformation of TG2 (PDB: 2Q3Z). These were
then subsequently ‘‘relaxed’’ by molecular dynamics conducted
in explicit water at 300 K (see Supplemental Experimental
Procedures).
The trajectories generated provided a rich source of informa-
tion that helped in the development of the new TG2 inhibitors.
One of the successfully exploited pathways relied on the obser-
vation that, during the dynamics trajectory, the water-soluble
ligands tend to adopt a specific conformation in the central
amino acid region. In fact, the dihedral N1-C2-C3-N4 empha-
sized in Figure 1A stabilized around 0 with a limited variation
of ±20. This key observation was the starting point for the
design of a new series of inhibitors.
In order to mimic the observed conformation for the central
N1-C2-C3-N4 region, we next introduced a piperazine scaffold,
as indicated in Figure 1B. The same three-atom linker was pre-
served between N4 and the carbonyl (vicinal to the warhead),
however, in order to facilitate the subsequent chemical modifi-
cations, a new nitrogen atom was introduced. One of the first
structures synthesized to validate this ‘‘restrained conformation’’
hypothesis exhibited the same activity range as the initial water-
soluble substrates (1a, Figure 1B). The irreversibility of the inhib-
itors was first confirmed by prior incubation of the compounds
with recombinant purified human TG2 and then subsequent
dilution prior to assay of the incubated enzyme as previously
described (Griffin et al., 2008). An indication of the hydrophilic
character of this derivative was observed experimentally during
the isolation step by freeze-drying the aqueous layer after
separation from the organic layer. In addition, an indication of
its cellular toxicity profile was undertaken in human umbilical1348 Chemistry & Biology 22, 1347–1361, October 22, 2015 ª2015 Ecord endothelial cells (HUVECs). As very little cellular toxicity
was observed after 72 hr at concentrations up to 100 mM
(Figure S1), this new molecule (1a) represented the starting
point for subsequent modifications. To rule out the effect of
any potential TG2 and FXIII present in the serum from the cell cul-
ture medium, which could eliminate the effect of the compounds
in the toxicity assay, the HUVECs were cultured in serum-free
endothelial cell medium in the presence of compounds 3h, 1h,
and 3e up to 72 hr, with no significant toxicity detected at the
concentrations used (Figure S2).
Optimization of Inhibitor Potency
The first step of our modification strategy focused on the central
amino acid region of the newly designed ligands. In order to
evaluate the effect of steric hindrance that could be generated
by additional substituents in this position, derivatives bearing
new core amino acids were synthesized (Figure 1C, Schemes
1 and 2). As summarized in Table 1A, the activity was lost
when using bulky substituents arising from phenylalanine (1l,
1k), the same but more moderate trend being observed for small
substituents (1i, 1j). It should also be mentioned that the chirality
of the stereogenic carbon atom seemed important, the analog
in the L-Ala series (1i) being favored over its D isomer (1j).
Our attention next focused on the electrophilic warhead re-
gion. Different groups were tested in order to evaluate their influ-
ence on the binding process. As a possible means of targeting
the extracellular space by limiting cell permeability, highly polar
warheads were attached to the newly designed skeleton. As
shown in Table 1B, the dialkylsulfonium moieties retained a
good inhibition range (1a, 1q), while the imidazolium warhead
induced a complete loss of activity (1s). It should be noted
that, in our initial water-soluble peptidic inhibitors, the same
imidazolium warhead maintained a good TG2 inhibition range
(Badarau et al., 2013b), suggesting the binding patterns of the
two classes of inhibitors are very different.
Our next approach was to design inhibitors containing lipo-
philic warheads, which were more likely to be cell permeable
and could be used to target the intracellular space. As the cata-
lytic CYS residue was revealed by the different available crystal
structures of TG2 to be hosted in a narrow tunnel (PDB: 2Q3Z,
Pinkas et al., 2007; PDB: 1KV3, Liu et al., 2002; PDB: 3LY6,
Han et al., 2010), our choice was focused on terminal Michael
acceptors such as acrylamides and vinylsulfonamides. Such
warheads possess an additional carbon atom in the electrophilic
region of the ligand, and it is likely that this will induce a different
conformation of the warhead around the catalytic CYS residue
compared with the sulfonium-based inhibitors. Table 1B shows
that both of these new warheads preserved a good inhibition
range (2a, 3a), the vinylsulfonamide having a more favorable
effect on binding.
Other modifications were performed in the carbamate region
(Table 1C). As this moiety was predicted by modeling to bind
in the hydrophobic pocket of the binding site (as revealed by
the crystal structure of the open-form conformation; Pinkas
et al., 2007), different-size aromatic carbamates were tested in
the first instance. In this case, the corresponding bromide pre-
cursors originally developed for inhibiting the serine proteases
(Schoellmann and Shaw, 1963), and which have high reactivity
with the enzymatic nucleophile, were also biologically evaluated.lsevier Ltd All rights reserved
Figure 1. Design and Synthesis of Lead TG2 Inhibitor Precursor
(A) Examples of dihedral angles defined by N1-C2-C3-N4 recorded during the molecular dynamics trajectory.
(B) Design of new peptidomimetic derivatives starting from the water-soluble inhibitors, R = SMe2.
(C) Scheme 1 for the synthesis of the amine precursors. (a) p-NO2-phenylchloroformate, N-methylmorpholine (NMM)/dichloromethane (DCM), 0
C, 2 hr; (b)
piperazine, triethylamine (TEA)/dimethylformamide, 0C to room temperature, 12 hr; (c) tert-butyloxycarbonyl (t-Boc)-Glu-OH, 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide, HOBt, NMM/DCM, room temperature, 12 hr; (d) trifluoroacetic acid/DCM, room temperature, 24 hr. Commercially available alcohols were acti-
vated as p-nitrophenyl carbonates 7 and subsequently reacted with piperazine at room temperature in order to give the desired mono-carbamates 8. A peptidic
coupling step with t-Boc-protected amino acids, followed by the acidic deprotection of the amines conducted to the key intermediates 5.
(D) Scheme 2 for the synthesis of the final derivatives. (a) Acryloyl chloride, TEA/acetonitrile, 0C to room temperature, 3 hr; (b) bromoacetyl bromide or
chloroacetyl chloride, TEA/DCM,78C to room temperature, 12h r; (c) dimethylsulfide/MeOH, room temperature, 24 hr; (d) acetyl bromide, TEA/DCM, 78C,
2 hr; (e) 2-chloroethylsulfonyl chloride, TEA/DCM,60C–0C, 4 hr. Starting from the previously obtained amines 5, various acylation agents were used in order to
obtain the final derivatives 1–4 as summarized in Scheme 2. In the case of polar dimethylsulfonium warhead, an additional nucleophilic substitution step was
conducted on the halomethylamide precursor 6.
(E) Toxicity profile of the fluorescent derivative 3h on HUVEC lines, after 24 hr (white), 48 hr (gray), and 72 hr (black) as described in the Experimental Procedures.
CNTL, control.If for the dimethylsulfonium and acrylamide warheads the
inhibition varies in the lower micromolar range, for the corre-
sponding halomethylketones the potency was increased to
the lower nanomolar range. However, their high cellular toxicity
profile for the halide precursors, particularly the more reactive
bromides, confirmed their limited pharmacological use.
A new set of inhibitors was prepared following the same
hypothesis of targeting the hydrophobic pocket of the active
site. An adamantyl moiety was chosen as the reference substit-
uent and its distance from the piperazine ring was systematically
varied in order to find an optimum for the interaction with the
enzyme. The corresponding tert-butyl carbamate was alsoChemistry & Biology 22, 1347–1synthesized. The best median inhibitory concentration (IC50) in
the ‘‘lipophilic’’ series was obtained for the acrylamide warhead
(3e), while in the ‘‘hydrophilic’’ series, the tert-butyl carbamate
(1m) outperformed its analogs (Table 1C).
Design and Characterization of a Fluorescent Probe
and Further Characterization of Lead Compounds
A dansyl fluorescent tag was attached to the central piperazine
scaffold to fully exploit the biological potential of this new class
of TG2-specific inhibitors, with the view to being able to pin point
and visualize the presence of the inhibitors, most importantly the
presence of the active enzyme located at a cellular level. Analogs361, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1349
Table 1. TG2 Inhibition Data on Varying the Central Amino Acid, the Warhead on the Initial Hit, and the Substituents in the Carbamate
Region
(A) Central Amino Acid:
O
O
N
N
O
Aa
N
H
O
S Br
(B) Warhead on the Initial Hit:
Lig
Compound Aa IC50 (mM ± SD) Compound R IC50 (mM ± SD)
1a Gly 1.4 ± 0.5 1a 1.4 ± 0.5
1j D-Ala 6.8 ± 2.0 1q 1.85 ± 0
1i L-Ala 0.7 ± 0.3 1s 100
1l D-Phe >100 2a 1.725 ± 0.11
1k L-Phe >100 3a 5.925 ± 0.11
(C) Substituents in the Carbamate Region:
Lig
Compound R1 R2 IC50 (mM ± SD)
6c 0.029 ± 0.019
1c 1.07 ± 0.1
3c 0.44 ± 0.057
(Continued on next page)
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Table 1. Continued
6d 0.015 ± 0.007
1d 1.5 ± 0.4
3d 2.1 ± 0
6n 0.00665 ± 0.00021
6b 0.0021 ± 0.0004
1b 3.3 ± 0.3
3b 6.3 ± 2.9
6e
Lig
0.0039 ± 0.0004
6o 0.00875 ± 0.00035
1e 0.889 ± 0.2
3e 0.125 ± 0.066
2e 0.875 ± 0.035
6f
O
Lig
0.00629 ± 0.0005
1f 0.775 ± 0.035
3f 1.625 ± 0.035
(Continued on next page)
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Table 1. Continued
1g
O
Lig
3.15 ± 0.92
3g 0.9 ± 0.14
1m 0.273 ± 0.11
IC50 values accompanied by the SDwere averaged from at least three independent experiments; they were otherwise obtained in a single experiment.in both water-soluble and lipophilic series were obtained and
evaluated for their activity on a battery of TGs (Table 2A). Com-
pound 3h had an excellent IC50 of 6 nM for TG2, as well as a
good toxicity profile when tested up to 100 mM (Figure 1E), and
showed selectivity for TG2 when assayed against TG1, TG3,
TG6, and Factor XIIIa (FXIIIa). A comparable TG selectivity profile
was also shown for 1hwith an IC50 value of 380 nM, again with a
good toxicity profile (Figure S1).
Measurement of the Ki andKinact of 3h and 1h using the gluta-
mate dehydrogenase coupled assay indicated high potency,
particularly 3h, with a Kinact of 0.387 min1, a Ki of 1.31 mM,
and a Kinact/Ki of 297,692 min1 M1. This was comparable
with the other high-potency non-dansylated inhibitor 3e
(IC50 125 nM), which had a calculated Kinact of 0.275 min
1, a
Ki of 1.63 mM, and a Kinact/Ki of 171,875 min1 M1. The other
fluorescent inhibitor, 1h, in line with its lower IC50 (380 nM), had a
Ki of 57 mM, a Kinact of 0.337 min1, and a Kinact/Ki of
5,830 min1 M1. Given the potential application of 3h and 1h
in TG2 conformational studies, it was important to demonstrate
that their reactivity was Ca2+ dependent. For this, recombinant
human TG2 was incubated for 30 min at 4C with either Ca2+
(1 mM) or GTP (1 mM), and then for a further 30 min in the pres-
ence of compound 3h (10 nM) or 1h (1 mM). Spin columns were
then used to remove excess inhibitor. Evaluation of TG2 activity
after removal of the excess inhibitor indicated that only the
enzyme incubated with GTP was active (Figure 2A), thus con-
firming the requirement of Ca2+ for the inhibitors 3h and 1h to
access the transamidating active site.
To rule out potential off-target effects of the inhibitors, inhibi-
tion of the cysteine proteases Caspase 3 and 7 was undertaken.
HUVECs were induced into apoptosis and the caspase activity
measured in situ in the presence and absence of 3h and 1h.
No inhibition of Caspase 3 or 7 was shown (Figure 2B). The
same results were obtained for the inhibitors 1e and 3e, which
carry the dimethylsulfonium and the acrylamide warheads,
respectively.
Other potent compounds were also tested for their specificity
toward TG2 compared with other TG family members. Bio-
tinylated TG-specific glutamine-containing peptides specific
for TG family members, including TG1, FXIIIa, TG3, and TG6,
were used in these assays (CovTests; Perez Alea et al., 2009).
Comparable IC50 values of these inhibitors for TG2 were de-
tected in both the CovTest and the biotin-cadaverine incorpora-1352 Chemistry & Biology 22, 1347–1361, October 22, 2015 ª2015 Etion assay. All derivatives from this series proved selective over
the TG1, TG3, and FXIIIa TGs with selectivity shown against
TG6 for compounds 1e, 1f, and 3f although less selectivity was
shown for TG6 with compound 3e (Table 2B). A moderate TG1
inhibition trend was observed for the halomethylamides. In the
case of TG2, however, the inhibition activities are in the lower
nanomolar range (>100-fold selectivity ratio). To rule out any
non-specific reaction of the inhibitors with TG1, TG3, and FXIIIa,
the dansylated probes 3h and 1h were incubated with these
three isoforms in the presence of Ca2+ and with EDTA, enzymes
were then separated by denaturing SDS gel electrophoresis
and western blotted for the detection of the dansyl group,
which showed negligible reactivity of the TG isoforms with either
inhibitor (Figure S3).
Further Characterization of the TG2 Inhibitors
Toxicity Studies
The toxicity profile of some of these new potent inhibitors was
evaluated in HUVECs using the XTT-based assay as described
previously (Wang and Griffin, 2013). The toxicity varied between
25 and 100 mM (Table S1 and Figure S1). As expected, in relation
to their high reactivity, the halomethylketones (6n, 6o) were the
most toxic compounds. The more hydrophilic inhibitors bearing
the dimethylsulfonium warhead were well tolerated by the
same cell lines with toxicity thresholds of <100 mM. Encouraging
results were also obtained for the compounds designed to be
more lipophilic, especially 3e, which has an inhibition activity
for TG2 in the nanomolar range (IC50 = 0.125 ± 0.066 mM).
Different toxicity profiles were observed between the acryl-
amide- and vinylsulfonamide-based derivatives (3e vs 2e), which
might be explained in part by their different chemical reactivities.
Confirmation of Covalent Interaction and Targeting
the Active Site Cys277 by 1h and 3h
The fluorescent inhibitor probes allowed us to demonstrate
that these compounds were targeting the active site Cys277
in their covalent reactivity. Pure recombinant wild-type (wt)
TG2 and its active site mutant Cys277Ser were incubated with
the compound 1h in the presence of Ca2+ for 3 hr. As a positive
control, the wt enzyme was incubated with the competitive
amine substrate monodansylcadaverine (MDC), which becomes
enzymatically incorporated into available g-glutamyl residues
on neighboring TG2 molecules.lsevier Ltd All rights reserved
Table 2. Inhibition profiles (IC50) for different TGs for both fluorescent derivatives and other selected potent TG2 inhibitors
(A)
N
S
O
N
O
N
O
N
H
R
O
Compound FXIIIa (mM) TG1 (mM) TG3 (mM) TG6 (mM) TG2 (mM) PSA (A˚2) R
3h >100 25 20 5 0.0061 ± 0.00042 90
Lig
1h >100 >100 >100 >10 0.38 ± 0.057 112
S
Lig
3e 37 2.2 11 2 0.125 ± 0.066 70
Lig
(B) Compound IC50
TG1 (mM) TG3 (mM) TG6 (mM) FXIIIa (mM)
1a >100 >100 NT >100
1c >100 >100 NT >100
3c >100 >100 NT >100
6d 5 65 NT >100
1d >100 >100 NT >100
3d >100 >100 NT >100
1b >100 >100 NT >100
6e 1 70 NT >100
1e >100 >100 >10 >100
6g 3 50 NT >100
1f >100 >100 >10 >100
3f >100 >100 >10 >100
3g >100 >100 NT >100
1m >100 >100 NT >100
For (A) in the case of TG2, the inhibition data (IC50) accompanied by standard deviation (SD) were averaged from at least three independent
experiments using the biotin cadaverine incorporation assay. For TG1, TG3, TG6 and Factor XIIIa the commercial TG-CovTest assay was used (Hitomi
et al., 2009; Fukui et al., 2013) with data obtained from one experiment. The polar surface area (PSA) values were calculated as described in the
Supplemental Experimental Procedures (B) Shows mean IC50 values obtained in a single experiment undertaken in duplicate using the commercial
TG-CovTest assay. NT = not tested.Following incubation, TG2 was separated on denaturing SDS-
PAGE and western blotted using an anti-dansyl antibody (Fig-
ure 2C). Bands were seen in the positive control containing the
MDC and in the wt enzymewhere the active site Cys277 is intact,
indicating covalent interaction of the inhibitor with TG2. In the
Cys277Ser mutant, no incorporation of MDC was detected in
a band that was indicative for TG2. Presence of the inhibitor
was not detected with the Cys277Ser mutant, suggesting that
fluorescent inhibitor 1h is specifically targeting the active site
Cys277.
Cellular Permeability
The cellular permeability profile for a subset of compounds was
investigated using the irreversible imidazolium-based inhibitor
R283 (Freund et al., 1994), which is cell permeable, and the
peptidic inhibitor R281, which is cell impermeable, as reference
as described previously (Baumgartner et al., 2004). This assay isChemistry & Biology 22, 1347–1based on the ability of compounds to permeate the cell and
inhibit intracellular TG2 activity after its activation by the eleva-
tion of intracellular Ca2+ using ionomycin. As initially designed,
the assay confirmed that acrylamide-based inhibitors 3e, 3f
and the fluorescent probe 3h penetrate the cell and inhibit intra-
cellular TG2 activity, contrary to the charged compounds 1e and
1f (Figure 2D). As a means of validating the permeability assay
used in these studies, the cell permeability of compounds 3h,
3e, and 1h was also determined in MDCKII-MDR1 cells. The
assay was conducted in the presence of the efflux transporter
inhibitor GF120918. Using this assay, the passive permeability
(P exact) of compounds 3h, 1h, and 3e was 649, 1.3, and
676 nm/s respectively, confirming that the acrylamide inhibitors
3h and 3e are cell permeable. In contrast, the positively charged
1h is cell impermeable. Measurement of the thermodynamic sol-
ubility of these same three compounds in PBS (pH 7.4) over 24 hr
was 24 mM for 3h, 1594.6 mM for 1h, and 698 mM for 3e.361, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1353
Figure 2. Characterization of the Lead Compounds for their Specificity and Cell Permeability
(A) Columns 2–5 showCa2+-dependent binding of 3hwith rhTG2. rhTG2pre-treatedwithCa2+ orGTPwas incubatedwith 3h (10 nM) or 1h (1 mM) for 30min at 4C.
Following removal of excessive inhibitors using 30-kDa cut off spin columns, bars 6 and 7 show the efficiency of the spin columns, where reaction mixes with
inhibitor alone (either 3h or 1h) were prepared and filtered through the spin columns prior to assay. Bars 8–10 show the efficacy of GTP binding, where enzymewas
incubatedwith 250mMCa2+ to showactivation of rhTG2 (bar 8) in the absenceofGTPandshowing that 1mMCa2+ activates TG2with 250mMGTPpresent (bar 10).
Samples with 1 mMGTP and 250 mM calcium were prepared in duplicate and one sample was processed through the spin column (bar 10) and the other sample
was not (bar 9) to evaluate whether the spin column affects GTP binding. A positive control incubated without inhibitor was used as 100% reference (bar 1).
(B) Effect of TG2 inhibitors 3h, 1h, 3e, and 1e on Caspase 3/7 activity. Following induction of apoptosis in HUVECs by staurosporine, caspase activity was
measured as described in the Experimental Procedures. Ctrl represents the negative control without any inhibitor; addition of the caspase inhibitor Z-VAD-FMK to
the assay represents the positive control.
(C) Western blotting showing covalent interaction of compound 1h with TG2 and demonstrating targeting of the active site Cys277 by 1h as described in the
Experimental Procedures.
(D) Cell permeability of TG2 inhibitors 3h, 1f, 3f, 3e, 1e in primary HUVECs. The assay measures the inhibition of the TG2-mediated incorporation of
N-(5-aminopentyl)biotinamide into intracellular proteins. R281, which is not cell permeable, was used as the 100% control. Experiments were undertaken as
described in the Experimental Procedures. *p < 0.05.
(E) Detection of dansyl inhibitor 3h in NIH3T3 cells. NIH3T3 cells transduced with TG2 containing Lentivirus were treated with 3h in the presence or absence
of ionomycin and 1e. Co-IP using the cell cytosol fractions was performed to detect the interaction between TG2 and 3h as described in the Experimental
Procedures.
(F) Non-denaturing gel electrophoresis. rhTG2 pre-treated with Ca2+ or GTP (concentrations as indicated in the figure), followed by incubation with 3h or 1h as
described in the Experimental Procedures. The samples were separated by non-denaturing PAGE and visualized using gel imaging.In Vitro ADME Properties of Compounds 3h, 1h, and 3e
Further characterization of lead compounds 3h, 1h and 3e by
in vitro ADME assays are shown in Table S2.Microsomal stability
assessed in human microsomes indicated that compounds
3h and 1h exhibited low and high stability, respectively, with
compound 3e demonstrating moderate stability. In contrast in
the cell health screen assessed in the hepatic cell line HepG2,
no significant effect was observed for any of the compounds
on mitochondrial potential, nuclear morphology, and membrane
permeability. Importantly, no significant effect was observed for
hERG liability with any of the compounds and their binding to hu-1354 Chemistry & Biology 22, 1347–1361, October 22, 2015 ª2015 Eman serum albumin and a-glycoprotein indicated that none of
them had very high binding.
Assaying for the Presence of Potential Intracellular
In Situ TG2 Activity/Open Conformation Using Dansyl
Derivative 3h
The measured cell permeability of the fluorescent inhibitor
3h, which requires TG2 to be in its Ca2+ bound open confor-
mation prior to its irreversible binding, should enable the
detection of TG2 in its open/relaxed conformation inside
the cell when combined with fluorescent microscopy and/orlsevier Ltd All rights reserved
co-immunoprecipitation (co-IP) studies. NIH3T3 cells trans-
ducedwith wt TG2were used to confirmwhether the intracellular
reaction of 3h with TG2 could take place. Figure 2E shows that
inhibitor 3h permeates into NIH3T3 cells and reacts with intracel-
lular TG2, which can be increased further in the presence of the
Ca2+ ionophore ionomycin (Figure 2E). This is demonstrated by
co-IP of the inhibitor/TG2 complex in the cytosolic fraction of
cells using an anti-dansyl antibody and TG2 revealed in this com-
plex using an anti-TG2 antibody bywestern blotting. Importantly,
the reactivity of 3h with intracellular TG2 was reduced by incu-
bating in the presence of the cell-permeable inhibitor 3e
(Figure 2E).
To confirm that the newly developed fluorescent inhibitors 3h
or 1h only interact with TG2 in its open Ca2+ bound conformation
and lock the enzyme into this conformation, wt recombinant TG2
pre-treated with Ca2+ or GTP was incubated with inhibitor 3h
and then separated by native PAGE. As shown in Figure 2F, 3h
and 1h in the presence of Ca2+ bind to TG2 and hold it in its
open conformation, while the binding of GTP, which holds TG2
in its closed conformation, blocks the interaction of 3h or 1h
with TG2 and gives rise to increased mobility.
HUVECs, which contain high levels of endogenous TG2, were
also used to verify our observations in TG2-transduced NIH3T3
cells. Cells were incubated in the absence or presence of the
Ca2+ ionophore ionomycin (positive control). Mouse endothelial
cells isolated from TG2/ mice were used as the negative
control together with HUVECs incubated with 3h in the pres-
ence of the cell-permeable non-dansylated inhibitor 3e. After
fixation of the cells and removal of any excess inhibitor by
washing, fluorescence microscopy revealed a faint intracellular
dansyl signal in the HUVECs without ionomycin treatment,
which was increased with ionomycin and reduced in the pres-
ence of inhibitor 3e. No dansyl signal was detected in the nega-
tive control mouse endothelial cells, which are null for TG2 after
fixing and washing out any excess inhibitor (Figure 3A). Further
confirmation that the dansyl inhibitor is targeting TG2 was ob-
tained by co-IP of the dansyl-labeled proteins in the cell cytosol
fractions of cell lysates and the detection of TG2 by western
blotting. TG2 was found to be present in the HUVECs with or
without ionomycin. The signal was reduced in the cells treated
with the inhibitor 3e and, importantly, as found with immunoflu-
orescent microscopy, totally absent in the TG2/ mouse
endothelial cells (Figure 3B). Hence, in both TG2-transduced
NIH3T3 cells and in HUVECs, TG2 appears to be present in
the intracellular environment in an open conformation and
able to react with inhibitor 3h, suggesting that the enzyme could
be active if suitable substrates are available to it, or, dependent
on its environment, is simply alternating between the open and
closed conformation.
Effect of 3h on TG2 Interaction with Syndecan-4
and its Translocation to the Cell Surface and ECM
The interaction between TG2 and syndecan-4 has been re-
ported to be not only essential for the externalization of the
enzyme onto the cell surface and deposition into the ECM
(Wang et al., 2012) but also for its pathological roles in fibrosis
(Scarpellini et al., 2014). Previous work from us and others
suggested the importance of TG2 crosslinking activity in patho-
logical conditions such as fibrosis, angiogenesis, and multipleChemistry & Biology 22, 1347–1sclerosis. Therefore, we next studied the effect of inhibitor 3h
on the binding of TG2 to syndecan-4 and its subsequent trans-
location into the ECM.
It has been reported that TG2 binding to syndecan-4 is favored
by the compact conformation (Wang et al., 2012) of the enzyme.
It has been shown in Figure 2F that the inhibitor 3h locks TG2 into
its open conformation, which would have a significant impact
on the binding of the enzyme to syndecan-4. Therefore, we
next studied the effect of 3h binding to TG2 on the enzyme’s
binding to cell surface heparan sulfates. Figure 3C shows that
in NIH3T3 cells, previously used to show TG2 binding to cell
surface syndecan-4, 3h significantly reduced the interaction
between TG2 and cell surface syndecan-4 following co-IP of
TG2 with anti-syndecan-4 antibody as previously documented
(Wang et al., 2012). Importantly, in these same cells, binding of
TG2 to 3h led to a dramatic reduction in the presence of the
enzyme on the cell surface and in the ECM (Figure 3D), which
paralleled a dramatic reduction in the deposition of fibronectin
(FN) into the ECM (Figure 3D).
Effects of Fluorescent TG2 Inhibitor 3h on Endothelial
Cell Function
In our previous report, using our first generation of peptidic TG
inhibitors, we showed that extracellular TG2 could be a potential
target in the treatment of VEGF-induced angiogenesis due to
its ability to block the deposition of FN, which is one of the impor-
tant ECM proteins required for matrix-bound VEGF signaling
(Wang et al., 2013). Given the ability of compound 3h to react
with both intracellular and extracellular HUVEC TG2, we tested
the effects of compound 3h on different but related endothelial
cell functions. Figure 4A shows that inhibitor 3h reduced the
deposition of FN into the ECM by HUVECs, which agrees with
its effect in NIH3T3 cells (Figure 3D). One further role of TG2 in
endothelial cell angiogenesis is in cell migration during tubule
formation (Wang et al., 2013), which is dependent on the cross-
linking activity of the enzyme. Figures 4B and 4C demonstrate
that compound 3h inhibited HUVEC migration in the wound-
healing assay and in Matrigel cord formation assays.
Potency of Inhibitor 3h in an In Vivo Model of
Hypertensive Nephrosclerosis
As a further means of demonstrating the potential application of
these new peptidomimetic inhibitors in human disease where
TG2 has been shown to act extracellularly, we next looked at
the effects of inhibitor 3h, which blocks both intracellular and
extracellular TG2 activity, on angiotensin II (AngII)-induced hy-
pertensive nephrosclerosis in mice. Before undertaking these
studies, we first gained an approximate cell IC50 for 3h by looking
at the inhibition of FN deposition in HUVECs and in mouse endo-
thelial cells, which in both cases gave an approximate IC50 for 3h
of 0.3 mM in human HUVECs and 0.4 mM in mouse endothelial
cells (Figure S4).
AngII and 3hwere delivered using a subcutaneously implanted
osmotic minipump (Azlet) over 14 days. Mice receiving AngII
alone together with inhibitor vehicle showed signs of increased
collagen deposition around the arterioles and, in some cases,
in the glomeruli and interstitial tubular space. In contrast, animals
receiving AngII plus compound 3h showed significantly reduced
(approx. 40%) collagen deposition in all these regions (Figure 5A)361, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1355
Figure 3. Intracellular Reactivity of Fluorescent Compound 3h with TG2 and its Effect on Enzyme Externalization
(A) Detection of in situ TG2 activity using the dansyl derivative 3h, HUVECs and TG2/ mouse endothelial cells (top panel) were treated as described in the
Experimental Procedures. The cells were pre-treated with (a–i) or without ionomycin (j–l), in the presence (g, h) or absence (a–f and j–l) of non-dansylated cell-
permeable inhibitor 3e, while TG2 antigen was visualized using anti-TG2 antibody Cub7402 (d–l). DAPI is shown in the top right hand corner of each image.
(B) Detection of TG2-dansyl derivative 3h complex in HUVECs and mouse TG2/ endothelial cells after co-IP and western blotting. HUVECs were treated
as described in (A). Cytosol fractions were collected and co-IP was undertaken using an anti-dansyl antibody as described in the Experimental Procedures.
The presence of TG2 was detected via western blotting. Rabbit IgG and TG2 knockout endothelial cells were used as the negative controls.
(C) Effect of inhibitor 3h on the interaction between TG2 and syndecan-4. Swiss3T3 cells transduced with wt TG2 were pre-treated with inhibitor 3h. Co-IP was
performed using anti-syndecan-4 antibody to pull down the immune complex and the presence of TG2 was detected via western blotting. The empty vector
transduced cells (vector) or the heparan sulfate binding mutant (HS2) TG2-transduced cells were used as the controls.
(D) Effect of 3h on TG2 externalization and deposition. The presence of TG2 in Swiss3T3 cells from (C) was detected via biotinylation of cell surface (CS) proteins
followed by western blotting. The matrix proteins were collected as described in the Experimental Procedures and the presence of TG2 was measured using
anti-TG2 antibody Cub7402 via western blotting. WCL, whole-cell lysate.with around 45% reduction around the blood vessels (Figure 5B)
in the kidneys of inhibitor-treated animals. No obvious signs of
toxicity were observed in the animals after inhibitor treatment.
DISCUSSION
In this paper, we report a new series of small-molecule peptido-
mimetic inhibitors that are selective for TG2 activity. Importantly,
we also demonstrate the biological impact of these inhibitors and
demonstrate their potential application in both cell and animal
models for the targeting of TG2 in diseases such as fibrosis
and pathological angiogenesis.
Contrary to the classic family of TG2 inhibitors represented
mainly by the peptidic inhibitors, this new series adds a new
member to the modest, but continuously increasing, family of
non-peptidic TG2 inhibitors. Sporadic examples have been
disclosed so far (Duval et al., 2005; Klock et al., 2011; Ozaki1356 Chemistry & Biology 22, 1347–1361, October 22, 2015 ª2015 Eet al., 2010, 2011; Pardin et al., 2008a, 2008b; Prime et al.,
2012; Schaertl et al., 2010). Their pharmacological characteriza-
tion in terms of potency, specificity, binding-site targeting,
toxicity, and cellular permeability still remains to be revealed.
In addition, a more recent report screening existing TG2 inhibi-
tors based on a weak electrophilic 3-bromo-4,5-dihydroisoxa-
zole (DHI) scaffold showed poor selectivity against TG1 (Klock
et al., 2014). Constructed on a piperazine core, this new scaffold
presented here has the advantage of an excellent selectivity
profile at least against four other members of the TG family
that were evaluated during our studies (TG1, TG3, TG6, and
FXIIIa). It should be noted, however, that another two groups
(Prime et al., 2012; Wityak et al., 2012) have reported pipera-
zine-based derivatives with interesting TG2 activities; however,
Prime et al. (2012) reported that their selectivity over the other
TGs (especially over FXIIIa) requires further optimization. Wityak
et al. (2012) reported that their lead inhibitor had an IC50 for TG2lsevier Ltd All rights reserved
Figure 4. Effect of Compound 3h on Endo-
thelial Cell Migration and Tubule Formation
(A) Representative images showing the effect of 3h
on FN deposition by HUVECs. 7 3 104 HUVECs
were seeded into chamber slides in the presence
or absence of 3h treatment for 72 hr. Immunoflu-
orescence staining was performed to detect the
extracellular FN as described in the Experimental
Procedures. Fluorescence images were captured
using an epifluorescence microscope from three
separate experiments.
(B) Representative images showing the effect of
3h on HUVEC migration in the wound-healing
assay. HUVECs were seeded into 12-well plates
until confluency. Wounds were introduced into
the monocell layer using 200-ml tips. The cells
were allowed to migrate for 6 hr and the closure of
the wounds was analyzed using ImageJ software
(n = 3). *p < 0.05.
(C) Representative images demonstrating the
inhibition of HUVEC cord formation on Matrigel by
3h. 96-well plates were pre-coated with Matrigel
and HUVECs were allowed to form cord structures
for 6 hr. The images from three separate experi-
ments were taken using a Nikon digital camera.of 14 nM with selectivity over TG1, TG3, TG6, and FXIIIa but no
cell or animal studies were undertaken on these compounds
although in vitro DMPK studies indicated they had low toxicity;
the authors indicated that improved ADME profiling was still
required for in vivo applications because of their low plasma
stability. Importantly, the straightforward synthetic route of the
compounds presented in this report gives easy access to various
modulations, allowing us to improve the toxicity profile of our
inhibitors up to 100 mM/72 hr, while controlling their cellular
access. However, like the compounds reported by Wityak
et al. (2012), further improvements on ADME characteristics
are still necessary for some of our lead compounds, in particular
improvements in microsomal stability and aqueous solubility
for 3h, although solubility may not be such an issue for in vivo po-
tency given that the solubility of 3h is >3,000 times the IC50 of 3h.
Moreover, the poor microsomal stability of 3h is unlikely to be
due to the piperazinyl moiety as suggested by Wityak et al.
(2012) given that compound 1h, which is a comparable structure
apart from the warhead, is microsomal stable.
Physiologically, TG2 is an enzyme that exists both in the intra-
and extracellular environment. Inside the cell, its Ca2+-depen-
dent crosslinking activity is thought to be tightly controlled by
the binding of GTP/GDP, which holds the enzyme in a compact
closed inactive conformation (Bergamini et al., 2011; Wang and
Griffin, 2012). However, TG2 is reported to be involved in a
number of human diseases where it acts both intracellularly
(e.g. cystic fibrosis, cancer progression, epidermal growth
factor receptor recycling) (Bergamini et al., 2011; Zhang et al.,
2013) and/or extracellularly, including matrix deposition, tissue
fibrosis, VEGF-dependent angiogenesis, and multiple sclerosisChemistry & Biology 22, 1347–1361, October 22, 2015(Wang and Griffin, 2012; Wang et al.,
2013). The development of a highly potent
cell-permeable fluorescent inhibitor spe-
cific for TG2, allowed us to test for thefirst time whether TG2, when inside the cell, can indeed exist in
both its potentially active open conformation as well as its
closed/compact conformation. Our data suggest that reactivity
of TG2 with the fluorescent inhibitor probe can take place in
the low Ca2+ intracellular environment of both HUVECs and
NIH3T3 cells, which can be further enhanced by using the Ca2+
ionophore ionomycin. Given that the reported Km app for Ca2+
for TG2 is around 3 mM (Hand et al., 1985), this suggests that
the conformation of the enzyme may also be regulated by other
binding factors in addition to Ca2+, which permits flexibility be-
tween the open and compact conformation and which, when in
the open conformation, allows the irreversible reaction with the
fluorescent TG2 inhibitor probe. Earlier fluorescence resonance
energy transfer studies with TG2 have also suggested that,
in certain localities of the cell, the enzyme may exist in its
open conformation (Pavlyukov et al., 2012). This may explain a
number of observations where TG2 has been reported to regu-
late a several cellular processes either through conformational
changes that regulate protein binding (Zhang et al., 2013) or
via its transamidating activity (Colak et al., 2011).
As referred to earlier, TG2 can be secreted into the ECM by a
non-conventional mechanism, which requires the cell surface
binding of heparan sulfates, such as syndecan-4, for its trans-
location into the ECM. This binding of TG2 to syndecan-4 at
the cell surface is favored by the enzyme being in its compact
closed conformation, suggesting that the enzyme is secreted
in this conformation or that this conformation is assumed once
it reaches the cell surface (Wang et al., 2012). Therefore,
our next questionwas to ask if the binding of an irreversible inhib-
itor inside the cell, which would hold the enzyme in its openª2015 Elsevier Ltd All rights reserved 1357
Figure 5. TG2 Inhibition Attenuates Angiotensin II-Induced Renal Fibrosis
Two groups of animals were used. In the first group, five C57BL/6 male mice (14 weeks old) were infused with AngII 1.1 mg/kg/day in 50%DMSO in PBS (pH 7.4)
for 2 weeks without TG2 inhibitor via a subcutaneously implanted osmotic pump (Alzet 1002) as previously described (Murdoch et al., 2014). In the second group,
compound 3h was infused in a similar manner at 25 mg/kg/day in 50% DMSO in PBS (pH 7.4) together with AngII over 14 days.
(A) Representative images of kidneys from the inhibitor- (lower panel) and non-inhibitor-(upper panel) treated animals.
(B and C) Averaged data of Sirius red/collagen staining in kidney sections showing staining (B) around arterioles (n = 4) and (C) total collagen staining (n = 5).
*p < 0.05.conformation, would interfere with both its translocation to the
cell surface and its deposition into the ECM.
Using NIH3T3 cells, we clearly show that treatment of these
cells with the fluorescent permeable inhibitor 3h reduces the
presence of TG2 at the cell surface and nearly completely blocks
translocation of the enzyme into the ECM, a finding that is
accompanied by the reduced deposition of FN. In HUVECs,
where we know TG2 also reacts with our fluorescent probe in-
side the cell, we also observed a large reduction in the deposition
of FN in the presence of this TG2 inhibitor. In relation to biological
functions of endothelial cells, this intracellular acting probe is
also a potent inhibitor of endothelial cord formation on Matrigel
and a potent inhibitor of endothelial motility, which is required
for endothelial tube formation (Wang et al., 2013). As a further
means of demonstrating the potential application of the new
peptidomimetic inhibitors in in vivo studies in a disease state
where TG2 acts extracellularly, we next looked at the effects
of inhibitor 3h on AngII-induced hypertensive nephrosclerosis
in mice. Mice receiving AngII plus compound 3h showed sig-
nificantly reduced (approx. 40%) collagen deposition across all1358 Chemistry & Biology 22, 1347–1361, October 22, 2015 ª2015 Eregions of the kidney with around a 45% reduction in collagen
deposition around the kidney arterioles when compared with
mice receiving AngII and vehicle.
Hence, our findings demonstrate that our new peptidomimetic
TG2 small-molecule inhibitors, which can react with TG2 inside
the cell and prevent export of the enzyme as well as block its
activity, provide an ideal therapeutic avenue for the treatment
of human diseases involving TG2.
SIGNIFICANCE
TG2 has been shown to be essential in a number of human
disease states, including fibrosis and angiogenesis. How-
ever, other transglutaminase family members sharing a
similarity in their structures generate obstacles in gener-
ating TG2-specific inhibitors with high potency and low
toxicity. Using molecular dynamics techniques, a series of
new peptidomimetic inhibitors against TG2 were produced
with excellent selectivity when tested against four other
members of the transglutaminase family (TG1, TG3, TG6,lsevier Ltd All rights reserved
and FXIIIa). A highly potent TG2 cell-permeable fluorescent
probe (IC50 = 6 nM; Kinact/Ki of 297,692 min
–1 M–1) was de-
signed and exploited in several biological studies. We
demonstrate that the reactivity of the inhibitor can take
place with TG2 in the low Ca2+ intracellular environment
of HUVECs and NIH3T3 cells, which is enhanced by using
the Ca2+ ionophore ionomycin. Importantly, reaction of
TG2 with this fluorescent inhibitor led to a loss of binding
of TG2 to cell surface syndecan-4 in NIH3T3 cells and inhibi-
tion of TG2 translocation into the ECM, which was paralleled
by a reduction in the deposition ofmatrix FN. Further studies
with HUVECs treated with this cell-permeable fluorescent
inhibitor revealed a significant reduction in FN deposition,
cord formation on Matrigel, and cell motility. As a means
of demonstrating the potential application of the new pepti-
domimetic inhibitors in vivo, where TG2 acts extracellularly
(Huang et al., 2009; Johnson et al., 2007), the effects of inhib-
itor 3h on Angiotensin II (AngII)-induced hypertensive neph-
rosclerosis in mice was investigated. Mice receiving AngII
plus compound 3h showed significantly reduced (approx.
40%) collagen deposition across all regions of the kidney
with around 45% reduction around blood vessels. Hence,
this new series of TG2-specific cell-permeable peptidomi-
metic inhibitors may be highly effective in targeting human
diseases involving extracellular TG2 via their ability to block
both protein crosslinking activity and enzyme export.
EXPERIMENTAL PROCEDURES
Synthetic and Analytical Methodology
The newly synthesized derivatives were characterized by IR spectroscopy,
proton and carbon-13 nuclear magnetic resonance spectroscopy (1H- and
13C-NMR), melting points, high resolution mass spectrometry, and had prop-
erties consistent with the proposed structures (see Supplemental Experi-
mental Procedures).
Biological Methodology
General experimental procedures were performed as described previously
(Wang et al., 2012, 2013,Wang andGriffin, 2012) and experimental information
is detailed in the Supplemental Experimental Procedures.
Reagents and Antibodies
The general reagents were purchased from Sigma-Aldrich (UK), unless stated
otherwise.
Chemical Synthesis of the Inhibitors
The synthesis of the inhibitors is described in the Supplemental Experimental
Procedures.
Cell Culture
HUVECs (Lonza) (Wang et al., 2013) and NIH3T3 cells (Wang et al., 2012) were
cultured as described previously (Supplemental Experimental Procedures).
TG2 Activity Assays
For measurement of TG2 activity, the incorporation of biotinylated cadaverine
into immobilizedN,N-dimethylcasein was used as described previously (Wang
et al., 2012).
For determination of the activity of TG1, TG3, TG6, and FXIIIa, commercial
microassays were used (TG-CovTest; Covalab) (Hitomi et al., 2009), according
to the manufacturer’s instructions. For comparable purposes, a number of
TG2 assays were also undertaken using this assay. Briefly, TG-specific bio-
tinylated peptides, including pepF11KA (FXIII pre-activated with thrombin),
pepK5 (TG1), pepT26 (TG2), pepE51 (TG3), or pepY25 (TG6) (Hitomi et al.,
2009; Fukui et al., 2013) were incubated with suitable TG family members inChemistry & Biology 22, 1347–1the presence of polyamine substrates immobilized onto 96-well microplates.
The incorporated biotinylated peptides were measured using horseradish
peroxidase-conjugated streptavidin and then measured using o-phenylenedi-
amine dihydrochloride substrates. The absorbance was measured at 490 nm
using a microplate reader.
Glutamate Dehydrogenase Coupled Assay Used for Kinact/Ki
Calculations
TG2 inhibitors were assayed in accordance with the method of Choi et al.
(2005) using the glutamate dehydrogenase coupled assay. Briefly, a reaction
mixture containing 4 mM CaCl2, 10 mM a-ketoglutarate, 0.2 U/ml glutamate
dehydrogenase, 0.12 mM NADH, 20 mg TG2, and 10 mM Cbz-Gln-Gly in
200 mM 3-(N-morpholino)ethanesulfonic acid (pH 7.1) was used in the assay.
The enzyme reaction was initiated by the addition of TG2 and the consumption
of NADHwasmonitored using different concentrations of inhibitor (10–500 nM)
by UV spectroscopy (340 nm, ε = 6,220 cm1 M1). Kinetic parameters (Kinact
and Ki) were obtained using the Dynafit 4.05.129 software (Kuzmic, 1996,
2009).
Cell Permeability Assay
By Measuring Inactivation of Intracellular TG2
To induce intracellular TG2 activity, HUVECs with high endogenous TG2 were
incubated with fresh growth medium with 0.5% FBS containing 1 mM ionomy-
cin and 1 mM biotin-cadaverine (Zedira) in the presence or absence of 50 mM
of TG2 inhibitors 3h, 1f, 3f, 3e, and 1e. The non-cell-permeable inhibitor R281
and the cell-permeable inhibitor R283 were used as the negative and positive
controls, respectively. After a 3-hr incubation, the cells were collected in
homogenization buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM
EDTA) and sonicated on ice. The cell membrane was pelleted at 60,000 3 g
for 60 min and the supernatant (the cytosol fraction) was used for the assay.
50 mg of total protein in 100 ml of the homogenization buffer was used in the
biotin-cadaverine incorporation assay as described previously by Wang
et al. (2012).
By the In Vitro Passive Cellular Permeability Assay
The permeability (P exact) of 3h, 1h, 3e across anMDCK-MDR1 cell monolayer
was measured at a starting concentration of 3 mM in the presence of
GF120918, an efflux inhibitor. The pH of the donor and receiver compartments
was 7.4 (Hank’s balanced salt solution).
Incubations were carried out in an atmosphere of 5%CO2 with a relative hu-
midity of 95% at 37C for 60 min. Apical and basolateral samples were diluted
for analysis by liquid chromatography-tandem mass spectrometry. The integ-
rity of the monolayers throughout the experiment was checked by monitoring
Lucifer yellow permeation using fluorimetric analysis (Tran et al., 2004).
Western Blotting for the Dansyl Inhibitor Interaction with rhTG2
1 mg of recombinant human TG2 (rhTG2), wt or the active site C277S mutant
protein, was incubated with the dansylated TG2 inhibitor 1h at 100 mM and
50 mM in the presence of 10 mM Ca2+ and 1 mM DTT in Tris-HCl buffer
(pH 7.4) for 30 min at room temperature. The primary amine substrate MDC,
which is incorporated into the available g-glutamyl residues of TG2 by the
enzyme, was used as the positive signal control sample, while non-labeled
rhTG2 was used as the negative control. The reaction was stopped by diluting
the samples into 23 Laemmli buffer and boiling at 95C for 5 min. The pres-
ence of dansyl was detected via western blotting (Wang et al., 2012, 2013)
by using a specific anti-dansyl antibody (Invitrogen).
The Targeting of In Situ TG2 Activity by Fluorescence Microscopy
Using the Dansyl Inhibitor 3h
HUVECs and TG2/ mouse endothelial cells were used in this study.
HUVECs were treated with 1 mM ionomycin in the presence or absence of
50 mM of 3e to pre-block the intracellular active TG2 for 3 hr, and the cells
were further treated with 5 mM 3h for another 2 hr. TG2/ endothelial cells
were treated in a comparable manner but were not exposed to the inhibitor
3e. For detection of endogenous TG2 activity, HUVECs were incubated
without ionomycin. After the incubation, the cells were washed three times
with pre-chilled methanol and fixed with methanol for 20 min at 20C.
Following blocking with 3% BSA in PBS (pH 7.4) for 30 min at 37C, the
cells were incubated with rabbit anti-dansyl antibody and revealed using a361, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1359
secondary tetramethylrhodamineisothiocyanate-conjugated antibody for a
2-hr incubation at 37C. The fluorescence signal was visualized using a Zeiss
epifluorescent microscope using a 603 objective.
Detection of TG2 Activity Using Co-IP
Immunoprecipitation of the intracellular TG2-dansyl inhibitor complex was
performed following the treatment of cells with 3h with or without pre-treat-
ment of 50 mM 3e (as described above). Cytosol fractions of HUVECs or
NIH3T3 cells transduced with TG2 were collected as described above.
Anti-TG2 antibody was used to pull down the TG2 immuno-complex and
SDS-PAGE and western blotting were then performed to detect the presence
of the dansyl group of 3h. TG2 knockout endothelial cells or non-TG2
transduced NIH3T3 cells, as well as a mouse IgG negative control antibody,
were used as the negative controls.
Animal Study
Animal studies were undertaken with full ethical approval and all procedures
carried out under license according to regulations laid down by Her Majesty’s
Government, United Kingdom (Animals Scientific Procedures Act, 1986) and
undertaken in accordance with the 3Rs. Two groups of five animals were
used. In the first group, C57BL/6 male mice (14 weeks old) were infused
with AngII 1.1 mg/kg/day in 50% DMSO in PBS (pH 7.4) for 2 weeks without
TG2 inhibitor via a subcutaneously implanted osmotic pump (Alzet 1002) as
previously described (Murdoch et al., 2014). In the second group, compound
3hwas infused in a similar manner at 25mg/kg/day together with AngII in 50%
DMSO in PBS (pH 7.4) over 14 days. After 14 days, kidneys from the treated
mice were frozen in OCT (CellPath) at an optimal temperature (150⁰C) using
isopentane; subsequently, 6-mm sections were prepared. Picrosirius red
staining was preformed to measure collagen staining as previously reported
(Murdoch et al., 2014). The collagen content was quantified as the percentage
area in a minimum of ten images per mouse using Image-Pro Plus version
5.0 (Media Cybernetics). The concentration (270 mM) of inhibitor used in the
pump was approximated from computer simulations to give the steady state
concentration in the mouse assuming an extensive distribution of the drug at
5 mM with a half-life of 1 hr.
Statistical Analysis
Data are expressed as the mean ± SD for at least three independent replicate
experiments (nR 3) unless otherwise stated. Statistical tests were undertaken
using InStat (GraphPad). Statistical analysis of the results was undertaken
using one-way ANOVA using a post-test depending on the requirement.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2015.08.013.
AUTHOR CONTRIBUTION
M.G., Z.W., and D.R. designed the experiments. E.B. performed the com-
pound synthesis and the modeling, with D.R. Z.W., A.C., T.T., C.M., M.B.,
and S.E.L. performed the biological experiments, and all authors analyzed
the data. M.G., Z.W., E.B., and D.R wrote the manuscript.
ACKNOWLEDGMENTS
The authors acknowledge EPSRCNational Mass Spectrometry Centre, Swan-
sea (UK) for recording the high resolution mass spectra. To GlaxoSmithKline,
UK, for undertaking the in vitro DMPK assays. Prof Soichi Kojima’s group
(Riken, Japan) for kindly providing the TG2 knockout endothelial cells. To Dr
Raj K. Singh Badhan (Aston University) for help in calculating the inhibitor
concentration used in the in vivo experiments following pharmokinetic simula-
tions. Fruitful discussions with Dr AlexandreMongeot and Dr Russell Collighan
(Aston University) are also acknowledged. M.G. was the major grant holder
that funded the work. E.B. was supported by a Marie Curie research grant
(‘‘TRANSCOM’’, FP7 No: 251506). A.C. was supported by a Marie Curie1360 Chemistry & Biology 22, 1347–1361, October 22, 2015 ª2015 Eresearch grant (‘‘TRANSPATH’’, FP7 No 289964). None of the authors of this
manuscript have a financial interest related to this work.
Received: April 9, 2015
Revised: August 4, 2015
Accepted: August 18, 2015
Published: October 8, 2015
REFERENCES
Badarau, E., Collighan, R.J., and Griffin, M. (2013a). Recent advances in the
development of tissue transglutaminase (TG2) inhibitors. Amino Acids 44,
119–127.
Badarau, E., Mongeot, A., Collighan, R.J., Rathbone, D.L., and Griffin, M.
(2013b). Imidazolium-based warheads strongly influence activity of water-sol-
uble peptidic transglutaminase inhibitors. Eur. J. Med. Chem. 66, 526–530.
Baumgartner, W., Golenhofen, N., Weth, A., Hiiragi, T., Saint, R., Griffin, M.,
and Drenckhahn, D. (2004). Role of transglutaminase 1 in stabilisation of
intercellular junctions of the vascular endothelium. Histochem. Cell Biol. 122,
17–25.
Bergamini, C.M., Collighan, R.J., Wang, Z., and Griffin, M. (2011). Structure
and regulation of type 2 transglutaminase in relation to its physiological
functions and pathological roles. Adv. Enzymol. Relat. Areas Mol. Biol. 78,
1–46.
Colak, G., Keillor, J.W., and Johnson, G.V. (2011). Cytosolic guanine nucledo-
tide binding deficient form of transglutaminase 2 (R580a) potentiates cell death
in oxygen glucose deprivation. PLoS One 6, e16665.
Choi, K., Siegel, M., Piper, J.L., Yuan, L., Cho, E., Strnad, P., Omary, B., Rich,
K.M., and Khosla, C. (2005). Chemistry and biology of dihydroisoxazole
derivatives: selective inhibitors of human transglutaminase 2. Chem. Biol.
12, 469–475.
Duval, E., Case, A., Stein, R.L., and Cuny, G.D. (2005). Structure-activity rela-
tionship study of novel tissue transglutaminase inhibitors. Bioorg. Med. Chem.
Lett. 15, 1885–1889.
Freund, K.F., Doshi, K.P., Gaul, S.L., Claremon, D.A., Remy, D.C., Baldwin,
J.J., Pitzenberger, S.M., and Stern, A.M. (1994). Transglutaminase inhibition
by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa
inactivation. Biochemistry 33, 10109–10119.
Fukui, M., Kuramoto, K., Yamasaki, R., Shimizu, Y., Itoh, M., Kawamoto, T.,
and Hitomi, K. (2013). Identification of a highly reactive substrate peptide
for transglutaminase 6 and its use in detecting transglutaminase activity in
the skin epidermis. FEBS J. 280, 1420–1429.
Griffin, M., Casadio, R., and Bergamini, C.M. (2002). Transglutaminases:
nature’s biological glues. Biochem. J. 368, 377–396.
Griffin, M., Mongeot, A., Collighan, R., Saint, R.E., Jones, R.A., Coutts, I.G.,
and Rathbone, D.L. (2008). Synthesis of potent water-soluble tissue transglu-
taminase inhibitors. Bioorg. Med. Chem. Lett. 18, 5559–5562.
Han, B.G., Cho, J.W., Cho, Y.D., Jeong, K.C., Kim, S.Y., and Lee, B.I. (2010).
Crystal structure of human transglutaminase 2 in complex with adenosine
triphosphate. Int. J. Biol. Macromol. 47, 190–195.
Hand, D., Bungay, P.J., Elliott, B.M., and Griffin, M. (1985). Activation of
transglutaminase at calcium levels consistent with a role for this enzyme as
a calcium receptor protein. Biosci. Rep. 5, 1079–1086.
Hitomi, K., Kitamura, M., and Sugimura, Y. (2009). Preferred substrate
sequences for transglutaminase 2: screening using a phage-displayed peptide
library. Amino Acids 36, 619–624.
Huang, L., Haylor, J.L., Hau, Z., Jones, R.A., Vickers, M.E., Wagner, B., Griffin,
M., Saint, R.E., Coutts, I.G., El Nahas, A.M., et al. (2009). Transglutaminase
inhibition ameliorates experimental diabetic nephropathy. Kidney Int. 76,
383–394.
Johnson, T.S., Fisher, M., Haylor, J.L., Hau, Z., Skill, N.J., Jones, R., Saint, R.,
Coutts, I., Vickers, M.E., El Nahas, A.M., et al. (2007). Transglutaminase inhibi-
tion reduces fibrosis and preserves function in experimental chronic kidney
disease. J. Am. Soc. Nephrol. 18, 3078–3088.lsevier Ltd All rights reserved
Klock, C., Jin, X., Choi, K., Khosla, C., Madrid, P.B., Spencer, A., Raimundo,
B.C., Boardman, P., Lanza, G., and Griffin, J.H. (2011). Acylideneoxoindoles:
a new class of reversible inhibitors of human transglutaminase 2. Bioorg.
Med. Chem. Lett. 21, 2692–2696.
Klock, C., Herrera, Z., Albertelli, M., and Khosla, C. (2014). Discovery of potent
and specific dihydroisoxazole inhibitors of human transglutaminase 2. J. Med.
Chem. 57, 9042–9064.
Kuzmic, P. (1996). Program DYNAFIT for the analysis of enzyme kinetic data:
application to HIV proteinase. Anal. Biochem. 237, 260–273.
Kuzmic, P. (2009). DynaFit–a software package for enzymology. Methods
Enzymol. 467, 247–280.
Liu, S., Cerione, R.A., and Clardy, J. (2002). Structural basis for the guanine
nucleotide-binding activity of tissue transglutaminase and its regulation of
transamidation activity. Proc. Natl. Acad. Sci. USA 99, 2743–2747.
Lortat-Jacob, H., Burhan, I., Scarpellini, A., Thomas, A., Imberty, A., Vive`s,
R.R., Johnson, T., Gutierrez, A., and Verderio, E.A. (2012). Transglutaminase-
2 interaction with heparin: identification of a heparin binding site that regulates
cell adhesion to fibronectin-transglutaminase-2 matrix. J. Biol. Chem. 287,
18005–18017.
Murdoch, C.E., Chaubey, S., Zeng, L., Yu, B., Ivetic, A., Walker, S.J.,
Vanhoutte, D., Heymans, S., Grieve, D.J., Cave, A.C., et al. (2014). Edothelial
NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunc-
tion through proinflammatory effects and endothelial-mesenchymal transition.
J. Am. Coll. Cardiol. 63, 2734–2741.
Ozaki, S., Ebisui, E., Hamada, K., Goto, J., Suzuki, A.Z., Terauchi, A., and
Mikoshiba, K. (2010). Potent transglutaminase inhibitors, aryl beta-aminoethyl
ketones. Bioorg. Med. Chem. Lett. 20, 1141–1144.
Ozaki, S., Ebisui, E., Hamada, K., Suzuki, A.Z., Terauchi, A., and Mikoshiba, K.
(2011). Potent transglutaminase inhibitors, dithio beta-aminoethyl ketones.
Bioorg. Med. Chem. Lett. 21, 377–379.
Pardin, C., Pelletier, J.N., Lubell, W.D., and Keillor, J.W. (2008a). Cinnamoyl in-
hibitors of tissue transglutaminase. J. Org. Chem. 73, 5766–5775.
Pardin, C., Roy, I., Lubell, W.D., and Keillor, J.W. (2008b). Reversible and
competitive cinnamoyl triazole inhibitors of tissue transglutaminase. Chem.
Biol. Drug Des. 72, 189–196.
Pavlyukov, M.S., Antipova, N.V., Balashova, M.V., and Shakhparonov, M.I.
(2012). Detection of transglutaminase 2 conformational changes in living cell.
Biochem. Biophys. Res. Commun. 421, 773–779.
Perez Alea, M., Kitamura, M., Martin, G., Thomas, V., Hitomi, K., and El Alaoui,
S. (2009). Development of an isoenzyme-specific colorimetric assay for tissue
transglutaminase 2 cross-linking activity. Anal. Biochem. 389, 150–156.Chemistry & Biology 22, 1347–1Pinkas, D.M., Strop, P., Brunger, A.T., and Khosla, C. (2007).
Transglutaminase 2 undergoes a large conformational change upon activa-
tion. PLoS Biol. 5, 2788–2795.
Prime, M.E., Andersen, O.A., Barker, J.J., Brooks, M.A., Cheng, R.K.,
Toogood-Johnson, I., Courtney, S.M., Brookfield, F.A., Yarnold, C.J.,
Marston, R.W., et al. (2012). Discovery and structure-activity relationship
of potent and selective covalent inhibitors of transglutaminase 2 for
Huntington’s disease. J. Med. Chem. 55, 1021–1046.
Scarpellini, A., Huang, L., Burhan, I., Schroeder, N., Funck, M., Johnson, T.S.,
and Verderio, E.A. (2014). Syndecan-4 knockout leads to reduced extracellular
transglutaminase-2 and protects against tubulointerstitial fibrosis. J. Am. Soc.
Nephrol. 25, 1013–1027.
Schaertl, S., Prime, M., Wityak, J., Dominguez, C., Munoz-Sanjuan, I., Pacifici,
R.E., Courtney, S., Scheel, A., and Macdonald, D. (2010). A profiling platform
for the characterization of transglutaminase 2 (TG2) inhibitors. J. Biomol.
Screen. 15, 478–487.
Schoellmann, G., and Shaw, E. (1963). Direct evidence for the presence of
histidine in the active center of chymotrypsin. Biochemistry 2, 252–255.
Tran, T.T., Mittal, A., Gales, T., Maleeff, B., Aldinger, T., Polli, J.W., Ayrton, A.,
Ellens, H., and Bentz, J. (2004). Exact kinetic analysis of passive transport
across a polarized confluentMDCK cell monolayermodeled as a single barrier.
J. Pharm. Sci. 93, 2108–2123.
Wang, Z., and Griffin, M. (2012). TG2, a novel extracellular protein with multiple
functions. Amino Acids 42, 939–949.
Wang, Z., and Griffin, M. (2013). The role of TG2 in regulating S100A4-medi-
ated mammary tumour cell migration. PLoS One 8, e57017.
Wang, Z., Collighan, R.J., Pytel, K., Rathbone, D.L., Li, X., and Griffin, M.
(2012). Characterization of heparin-binding site of tissue transglutaminase:
its importance in cell surface targeting, matrix deposition, and cell signaling.
J. Biol. Chem. 287, 13063–13083.
Wang, Z., Perez, M., Caja, S., Melino, G., Johnson, T.S., Lindfors, K., and
Griffin, M. (2013). A novel extracellular role for tissue transglutaminase in
matrix-bound VEGF-mediated angiogenesis. Cell Death Dis. 4, e808.
Wityak, J., Prime, M.E., Brookfield, F.A., Courtney, S.M., Erfan, S., Johnsen,
S., Johnson, P.D., Li, M., Marston, R.W., Reed, L., et al. (2012). SAR develop-
ment of lysine-based irreversible inhibitors of transglutaminase 2 for
Huntington’s disease. ACS Med. Chem. Lett. 3, 1024.
Zhang, J., Antonyak, M.A., Singh, G., and Cerione, R.A. (2013). A mechanism
for the upregulation of EGF receptor levels in glioblastomas. Cell Rep. 3, 2008–
2020.361, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1361
